P/B
—
NeuroSense Therapeutics
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.
$9.6M
Market Cap • 9/28/2026
2017
(9 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
Israel
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
—
EPS
—
Market Cap
Market Cap
9,6M
EV
9,4M
EV/Revenue
0
EV/EBITDA
-1
EV/EBIT
-1
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-55%
Total Yield
-55%
Payout
0%
Retained Earnings
-51,3M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
31,3%
Capex/OCF
-0,1%
SBC/OCF
—
% PPE
5,8%
% Goodwill
0%
ROE
761,2%
ROIC
—
Growth
CAGR Op. Income 5Y
13,2%
CAGR Net Income 5Y
13,7%
CAGR EPS 5Y
-17,4%
CAGR OCF 5Y
50,1%
Leverage
N.D./EBITDA
0
Debt/Equity
0%
Current Ratio
0,3
Quick Ratio
0,3
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!